Next-generation Sequencing Market (By Product: Consumables Platforms, Services, Blockers; By Application: Diagnostics, Biomarkers and Cancer, Reproductive Health, Personalized Medicine, Agriculture and Animal Research, Others; By Technology: Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing, and Others; By End User) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032
The global next-generation sequencing market size was valued at USD 11.57 billion in 2023 and is expected to surpass around USD 44.69 billion by 2032, poised to grow at a remarkable CAGR of 16.20% from 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. next-generation sequencing market was estimated at USD 2.74 billion in 2023 and is projected to expand around USD 10.36 billion by 2032, at a CAGR of 15.90% between 2023 to 2032.
Based on the region, the North America segment dominated the global next-generation sequencing market in 2022, in terms of revenue and is estimated to sustain its dominance during the forecast period. The direct presence of key manufacturers, the active government support, and the rising cancer prevalence are the primary drivers of the market expansion in North America throughout the forecast period.
Next-generation Sequencing Market Revenue Share (%), by Geography, Global, 2022
On the other hand, the Europe is estimated to be the most opportunistic segment during the forecast period. Due to increased research expenditure, a focus on precision pharmaceuticals, and strategic alliances, the next-generation sequencing (NGS) market in Europe is expected to grow.
Next-generation sequencing (NGS) is a massively parallel sequencing method that provides scalability, ultra-high throughput, and high speed for determining the order of nucleotides throughout the genome. Because it involves the preparation of the material for the subsequent sequencing reaction, DNA pre-sequencing is one of the most important processes in the overall sequencing protocol. Globally, NGS is becoming more incorporated into clinical laboratory analysis, testing, and disease diagnostics in the healthcare sector. In pharmacogenomic, next-generation sequencing (NGS) is commonly used to speed up the drug discovery process.
The growth of the overall market is predicted to be driven by main reasons such as increased research and development activities utilizing NGS technologies, growing uses of NGS in clinical diagnosis, and discovery applications that require next-generation sequencing (NGS) technology.
The increased genome mapping programs, increased applications of next-generation sequencing (NGS), increased healthcare expenditure, and technological advancements in sequencing platforms are all driving the global next-generation sequencing market growth during the forecast period. However, during the projection period, the scarcity of experienced specialists, as well as ethical and regulatory limitations connected with next-generation sequencing (NGS), is projected to impede the market growth during the forecast period.
The emergence and domination of the next-generation sequencing (NGS) market has resulted from the growing demand for cost-effective, quick, and accurate DNA sequencing data interpretation, as it enables for the sequencing of large amounts of DNA in a single run, making illness diagnosis and research easier. The next-generation sequencing makes a significant contribution to genomics. The next-generation sequencing market is expected to benefit from the launch of genomics programs in a number of nations. The introduction of next-generation sequencing (NGS)-based diagnostics, as well as active government assistance, is also important drivers of the market growth.
The use of molecular diagnostic methods in clinical microbiology laboratories has increased significantly in recent years. As molecular diagnostic technologies such as next-generation sequencing (NGS) may detect the presence of nucleic acids. The next-generation sequencing technologies are quick and don’t require specimen growth in culture. The researchers can use next-generation sequencing texts to detect numerous diseases concurrently and directly from a sample. The disadvantages of methods like polymerase chain reaction (PCR) are thought to be driving force behind the next-generation sequencing (NGS) market’s overall expansion during the forecast period.
| Report Coverage | Details |
| Market Size In 2023 | USD 11.57 Billion |
| Growth Rate | CAGR of 16.20% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product, Application, Technology, Region |
| Companies Mentioned | BGI Group, F. Hoffmann-La Roche AG, Pacific Biosciences of California Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Precigen Inc., Illumina Inc., Qiagen N.V., PerkinElmer Inc., PierianDx Inc. |
Due to advancements in molecular genetics technology and a surge in demand for novel pre-sequencing products and kits that perform DNA fragmentation, size selection, target enrichment, and other functions, the consumables segment dominated the next-generation sequencing (NGS) market by product in 2022 and is expected to do so throughout the forecast period.
On the other hand, due to advancements in technology based on single-molecule real-time sequencing (SMRT) sequencing and an increase in the use of cloud computing for next-generation sequencing (NGS) data storage, the services segment is likely to have significant market growth during the forecast period.
Based on the application, the biomarker and cancer dominate the next-generation sequencing market during the forecast period. Due to an increase in cancer occurrence and advancements in next-generation sequencing (NGS) technology, the market is likely to grow over the forecast period.
On the other hand, the personalized medicine is expected to grow at rapid pace during the forecast period. Due to increased demand for drug treatment, advancements in research and development in the healthcare sector, and increased awareness of next-generation sequencing (NGS) testing in the pharmaceutical and biotechnological industries, the personalized medicine segment is expected to see significant next-generation sequencing market growth over the forecast period.
Based on end user, the next-generation sequencing market is segmented into academic and research centers, pharmaceutical and biotechnology companies, hospitals and clinics, clinical research, others.
The academic research segment accounted largest revenue share of over 53% in 2022 and expected to remain its dominance dusring the forecast period 2023 to 2032. The Clinical research segment is projected to grow at fastest growing rate from 2023 to 2032 due to the rising penetration of NGS-based diagnostic tests.
Based on the technology, the sequencing by synthesis dominates the next-generation sequencing market during the forecast period. The increasing availability of next-generation sequencing (NGS) systems based on sequencing by synthesis technology is responsible for the substantial share of the sequencing by synthesis technology system.
On the other hand, the ion semiconductor sequencing is expected to grow at rapid pace during the forecast period. When compared to other DNA sequencing methods, ion semiconductor sequencing technology is sophisticated and cost-effective, affecting segment growth. Thus, the ion semiconductor sequencing technique’s vast range of applications will propel the next-generation sequencing market (NGS) growth.
Key Companies & Market Share Insights
The next-generation sequencing market is characterized by fierce competition among the key market players. The launch of novel platforms that are fast, small, and less expensive is one of the strategies used by the companies to improve their market position. Cerba Research, for example, announced two new COVID-19 exploratory tools in January 2021, one PCR-based and the NGS-based to enhance research and development for vaccine development against coronavirus.
Segments Covered in the Report
By Product
By Application
By Technology
By End User
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Next Generation Sequencing Market
5.1. COVID-19 Landscape: Next Generation Sequencing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Next Generation Sequencing Market, By Product
8.1. Next Generation Sequencing Market, by Product Type, 2023-2032
8.1.1. Consumables Platforms
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Services and Nerve Blockers
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Next Generation Sequencing Market, By Application
9.1. Next Generation Sequencing Market, by Application, 2023-2032
9.1.1. Diagnostics
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Biomarkers and Cancer
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Reproductive Health
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Personalized Medicine
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Agriculture and Animal Research
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Next Generation Sequencing Market, By Technology Type
10.1. Next Generation Sequencing Market, by Technology Type, 2023-2032
10.1.1. Sequencing by Synthesis
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Ion Semiconductor Sequencing
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Sequencing by Ligation
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Pyrosequencing
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Single Molecule Real Time Sequencing
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Next Generation Sequencing Market, By End User Type
11.1. Next Generation Sequencing Market, by End User Type, 2023-2032
11.1.1. Academic and Research Centers
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Pharmaceutical and Biotechnology Companies
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Hospitals and Clinics
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Clinical Research
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Next Generation Sequencing Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.1.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.2.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.3.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.4.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.5.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End User Type (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Technology Type (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End User Type (2020-2032)
Chapter 13. Company Profiles
13.1. BGI Group
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. F. Hoffmann-La Roche AG
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pacific Biosciences of California Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Thermo Fisher Scientific Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Agilent Technologies Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Precigen Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Illumina Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Qiagen N.V.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. PerkinElmer Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. PierianDx Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
